Lifecore Biomedical, Inc. De (LFCR) Gains from Investment Securities (2010 - 2025)

Lifecore Biomedical's Gains from Investment Securities history runs 16 years deep, the most recent figure standing at -$7.6 million for Q2 2025.

• In Q2 2025, Gains from Investment Securities fell 14407.55% year-over-year to -$7.6 million; the TTM figure through May 2025 stood at -$4.9 million (down 3341.45% YoY), while the FY2025 annual figure was -$7.8 million, down 5215.79% from the prior year.
• Gains from Investment Securities was -$7.6 million for Q2 2025 at Lifecore Biomedical, down from -$333000.0 in the prior quarter.
• In the past five years, Gains from Investment Securities ranged from a high of $2.4 million in Q4 2024 to a low of -$7.6 million in Q2 2025.
• Historically, Gains from Investment Securities has averaged -$718266.7 across 5 years, with a median of $53000.0 in 2024.
• The sharpest annual moves came in 2024 and 2025: Gains from Investment Securities jumped 5433.33% in 2024, then sank 14407.55% in 2025.
• A 5-year view of Gains from Investment Securities shows it stood at $428000.0 in 2021, then plunged by 120.09% to -$86000.0 in 2022, then soared by 47.67% to -$45000.0 in 2023, then surged by 5433.33% to $2.4 million in 2024, then sank by 415.96% to -$7.6 million in 2025.
• The last three Gains from Investment Securities figures came in at -$7.6 million (Q2 2025), -$333000.0 (Q1 2025), and $2.4 million (Q4 2024), per Business Quant data.